Browse Neurology Articles by Topic

Treatment of Tuberculosis and Latent Tuberculosis Infection

The treatment of pulmonary tuberculosis is divided into an initial phase of four drugs for two months.

Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis

By Malcolm Robinson, MD, FACP, FACG Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca, and Centocor.

Pramlintide Acetate Injection (Symlin)

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study. A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics. Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.

Full July 15, 2005, Issue in PDF

Rifamixin for the Prevention of Traveler’s Diarrhea?

Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.

Vitamin E, Donepezil and MCI

By Norman R. Relkin, MD, PhD Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus. Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.

Clinical Briefs By Louis Kuritzky, MD

White-Coat HTN Make Diabetics Walk Treatment of Complicated Grief

Full June 29, 2005, Issue in PDF

Does Stress Management Improve Markers of Cardiovascular Disease?

By Ralph R. Hall, MD, FACP Emeritus Professor of Medicine, University of Missouri, Kansas City School of Medicine Disclosure; Dr. Hall is a consultant for Sanofi-Aventis. Synopsis: Exercise and stress management improved markers of cardiovascular disease more than usual care alone.

Fluid Balance in Runners: Getting it Right

By Joseph E. Scherger, MD, MPH Clinical Professor, University of California, San Diego Disclosure; Dr. Scherger reports no financial conflicts to this field of study.